向雄激素受体信号,以增强癌症免疫疗法
David A Bader1, Binita Chakraborty2, Donald P McDonnell3
1Department of Medicine, Duke University School of Medicine, Durham, NC, USA; Division of Medical Oncology, Duke University School of Medicine, Durham, NC, USA; Duke Cancer Institute, Durham, NC, USA; Duke Molecular Physiology Institute, Durham, NC, USA; Physician-Scientist Training Program, Duke University School of Medicine, Durham, NC, USA.
雄激素受体 (AR) 信号抑制抗癌免疫力. 虽然AR抑制可以促进T细胞功能,但最近的试验将AR抑制与前列腺癌中免疫检查点抑制剂结合起来,没有显示出临床益处.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
背景情况:
- 与女性相比,男性的癌症发病率和死亡率更高.
- 雄激素受体 (AR) 信号被认为是癌症性别差异的驱动因素.
- AR信号可以抑制身体的适应性抗癌免疫反应.
研究的目的:
- 讨论了解AR信号和抗癌免疫的最新进展.
- 总结了定义AR信号在癌症免疫反应中的作用的研究.
- 在临床试验中提出将AR抑制与免疫疗法整合的策略.
主要方法:
- 关于AR抑制和免疫反应的临床前研究的综述.
- 分析最近的第三期临床试验,结合AR抑制和免疫检查点阻塞在前列腺癌.
- 综合关于AR信号在抗癌免疫中的作用的当前研究.
主要成果:
- 临床前数据表明AR抑制可以增强T细胞功能,并使瘤对免疫检查点抑制剂敏感.
- 最近在前列腺癌的第三期试验中,将AR抑制与免疫检查点阻塞相结合,未能显示临床益处.
- 在调节抗癌免疫力方面,AR信号的确切作用需要进一步阐明.
结论:
- 尽管有前临床数据很有希望,但AR抑制和免疫检查点阻塞的结合尚未转化为前列腺癌的临床益处.
- 需要进一步的研究来了解AR信号与抗癌免疫之间的复杂相互作用.
- 优化的临床试验设计是必要的,以有效地整合AR抑制策略与免疫治疗.
更多相关视频
09:56A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
08:46A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
相关概念视频
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
Mitogens and the Cell Cycle
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
